News | May 13, 2015

Modified Citrus Pectin Enhances Radiation Therapy in Prostate Cancer Treatment

Study suggests it may overcome prostate cancer radio-resistance

modified citrus pectin, MCP, prostate cancer, radio-resistance, Tel Aviv

May 13, 2015 — Scientists at Tel Aviv Medical Center, Israel, have found that oral modified citrus pectin (MCP) enhances the anti-cancer and anti-metastatic effects of radiation therapy in the treatment of androgen-independent (AI) aggressive prostate cancer cells. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015.

The study, titled, “Combined effect of modified citrus pectin (MCP) and ionizing radiation on viability and metastatic activity of prostate cancer cells,” demonstrated that MCP enhanced radiation treatment of prostate cancer by increasing radio-sensitivity of aggressive prostate cancer cells. Previous research demonstrated MCP’s anti-cancer actions, including induction of apoptosis, inhibition of proliferation and metastasis, and synergy with chemotherapeutic drugs and botanical compounds. MCP also protects against inflammation and fibrosis, via its binding affinity for the pro-inflammatory protein, galectin-3. However, this is the first study to clearly demonstrate MCP’s ability to radio-sensitize aggressive, AI prostate cancer cells.

“Radio-resistance is a key contributor to the decreasing effectiveness of radiation treatment for aggressive, androgen-independent prostate cancer. The potential of MCP to increase radio-sensitivity in aggressive prostate cancer is encouraging news for researchers and patients alike,” stated Isaac Eliaz, M.D., MS, LAc, one of the study’s lead investigators. “Furthermore, MCP’s ability to protect against inflammation and fibrosis via galectin-3 inhibition helps to minimize fibrotic damage to healthy tissues – a common side effect of radiation treatment.”

In the study, researchers used cellular viability and clonogenic assays to evaluate the effects of MCP on the viability of AI-prostate cancer cell lines DU-145, PC-3, and CI-1, alone and in combination with radiation treatment. Alone, MCP induced a dose-dependent decrease in cell viability. The combination of MCP and radiation treatment produced synergistic effects against prostate cancer cell lines DU-145 and CI-1, and additive effects against cell line PC-3. Treatment of cells with MCP reduced cell migration by 20 percent and reduced cell invasion by 40 percent. These results demonstrate MCP to be an effective radio-sensitizer of AI prostate cancer cells, suggesting that MCP may be used to selectively enhance cytotoxicity and overcome radio-resistance.

The MCP used in the study is made from the pith of citrus fruit peels, and modified to a specific molecular weight and structure using a proprietary enzymatic and pH process. Previous research has demonstrated MCP’s benefits in a number of cancer types, including breast, prostate, colon and others. MCP is also an effective chelator of toxic metals, as well as a selective immune enhancer shown to activate and increase cytotoxicity of NK cells ex vivo.

For more information: www.betterhealthpublishing.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Overlay Init